Clinical and radiologic improvements in mitochondrial encephalomyelopathy following sodium dichloroacetate therapy.
We administered sodium dichloroacetate (DCA), which reduces the circulating lactate and pyruvate concentrations by stimulating the activity of the pyruvate dehydrogenase complex (PDHC), to three children with mitochondrial encephalomyelopathy. Significant clinical, biochemical and radiologic improvements were obtained following DCA therapy (approximately 30 mg/kg per day, divided into three doses). All three patients had non-pyruvate dehydrogenase complex (PDHC) deficiencies: two exhibited Leigh syndrome (complex I deficiency and unknown etiology), and one abnormal myelination (multienzyme deficiency), demonstrated on magnetic resonance imaging (MRI). The lactic and pyruvic acid concentrations in serum and cerebrospinal fluid (CSF) were decreased significantly by the oral DCA treatment. The lactic acid peak on MR spectroscopy also markedly decreased in parallel with the CSF level. In addition, the brain lesions observed on MRI were improved in all patients. No exacerbation was observed in any of the patients, who have been followed-up more than 21 months following the DCA therapy. These results suggest that DCA therapy should be considered in all patients with a mitochondria-related enzyme deficiency.
Kimura
S
S
Department of Pediatrics, Urafune Hospital, Yokohama City University, Yokohama, Kanagawa, Japan.
Ohtuki
N
N
Nezu
A
A
Tanaka
M
M
Takeshita
S
S
D001921:Brain / Q000473:pathology; D002493:Central Nervous System Diseases / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D003999:Dichloroacetic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007223:Infant; D007888:Leigh Disease / Q000175:diagnosis* / Q000188:drug therapy* / Q000503:physiopathology; D008279:Magnetic Resonance Imaging; D008297:Male; D009186:Myelin Sheath; D013116:Spinal Cord / Q000473:pathology
D003999:Dichloroacetic Acid